Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences reported positive Phase 1 dose escalation data for CB-011, an off-the-shelf CAR-T therapy for relapsed/refractory multiple myeloma. In a cohort of 12 heavily pretreated, BCMA-naive patients, CB-011 achieved a 92% overall response rate, 83% complete response rate, and 91% MRD negativity, with 50% of patients maintaining deep response at 15 months.
Key figures
- Drug Name
- CB-011
- Phase Of Trial
- Phase 1
- Orr
- 92%
- Cr rate
- 83%
- Mrd negativity
- 91%
- Durability 15mo
- 50%
- Patients treated
- 48
- Bcma naive cohort size
- 12
- Median follow up months
- 17.7
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.